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Abstract The authors present a case of a 56-year-old man
with altered mental status. Magnetic resonance imaging
(MRI) of the brain revealed non-enhancing abnormalities
on T2 and FLAIR imaging in the brainstem, cerebellum,
and cerebrum. Immunohistochemisty demonstrated precur-
sor T-cell lymphoblastic lymphoma. After treatment with
methotrexate, he improved clinically without focal senso-
rimotor deficits and with improving orientation. MRI
showed almost complete resolution of brainstem and
cerebral lesions. To the authors’ knowledge, there are only
five previous reports of primary central nervous system T-
cell lymphoblastic lymphoma. Since treatable, it deserves
consideration in patients with altered mental status and
imaging abnormalities that include diffuse, non-enhancing
changes with increased signal on T2-weighted images.
Keywords T-cell lymphoblastic lymphoma . Primary CNS
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Chemotherapy
Introduction
Primary central nervous system (CNS) lymphomas account
for 5% of primary brain tumors, of which the vast majority
are of B-cell origin [2]. Although rare, the incidence of
primary CNS lymphoma appears to be increasing in both
immunocompromised and immunocompetent patients, even
when controlling for improving diagnostic technology [18].
Primary CNS T-cell lymphomas (TPCNSL) constitute
between 3.6 and 8.5% of primary CNS lymphomas in
France and Japan, respectively [2, 12]. In the largest study
in the United States, 2% of primary CNS lymphomas were
of T-cell origin [9]. Brainstem involvement is even more
rare, occurring in 9% of TPCNSL [17, 22]. Primary CNS
lymphomas are classified morphologically similar to sys-
temic lymphomas. Primary CNS lymphomas are most
commonly diffuse large-cell lymphomas, with lymphoblas-
tic types occurring in only 2.9% [15]. To our knowledge, of
the reports which describe histologic analysis, only five
report the lymphoblastic type of TPCNSL (Table 1) [4, 11,
19–21]. In this report, we present a 56-year-old man with
altered mental status and diffuse non-enhancing magnetic
resonance imaging (MRI) abnormalities in the brainstem,
cerebellum, and cerebral hemisphere with pathology find-
ings consistent with primary brain T-cell lymphoblastic
lymphoma.
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Clinical details
History and Examination The patient is a 56-year-old
immunocompetent white man with a 6-week history of
headaches, memory disturbance, decreased hearing, diplo-
pia, and weakness. The patient presented to an outside
hospital for increasing confusion, lethargy, and vomiting.
History was significant for a recent tick bite with positive
Lyme disease serology. Prior MRI had demonstrated
abnormal enhancement of cranial nerves III and IV
bilaterally. The presumptive diagnosis had been Lyme
neuroborreliosis and the patient had undergone treatment
with doxycycline and prednisone prior to presentation.
Improvement was noted, however it was short-lived.
Lumbar puncture was performed at the outside hospital
which showed mild lymphocytic pleocytosis and oligoclo-
nal bands with 59 white blood cells (WBC) per mm3
(normal<5), glucose of 36 mg/dl, and protein 154 mg/dl
(normal 18-58). Lyme polymerase chain reaction testing of
the cerebrospinal fluid (CSF) was negative. On exam, the
patient was afebrile, hypertensive 205/105, and had a
nonfocal neurologic exam. There was no evidence of
nuchal rigiditiy, rashes, lymphadenopathy, or joint swelling.
Laboratory studies were significant for 20,700 WBC per
mm3 and an erythrocyte sedimentation rate of 13 mm/h.
HIV status was negative. The patient’s neurologic status
subsequently worsened requiring tracheal intubation for
airway protection. The patient, now unresponsive, was
transferred to the Virginia Commonwealth University
Health System for further evaluation and management.
Imaging Repeat imaging was performed shortly after
presentation to our hospital. Computed tomography (CT)
of the brain revealed subtle low attenuation in the brainstem
without evidence of hemorrhage, infarction, or mass. Brain
MRI revealed widespread, nearly symmetric, non-
enhancing areas with increased signal on T2 (Fig. 1a) and
FLAIR (Fig. 1b) imaging in the pons, with extension to the
medulla and midbrain, cerebellum, right frontal cortex, and
bilateral temporal lobes, with extension to the Sylvian
region and right parietal lobe. There was no mass effect or
midline shift.
Operation and postoperative course The patient underwent
small right craniotomy for open biopsy of the frontal lesion
and stereotactic transfrontal, transpeduncular biopsy of the
pontine area of T2 signal abnormality. Pathologic exami-
nation was consistent with lymphoblastic type TPCNSL
and is described below. Normal chest and abdominal CTs
supported the CNS origin of the disease. Postoperatively,
the patient remained markedly obtunded with impaired
respiratory function, requiring tracheostomy and percutane-
ous endoscopic gastrostomy tube placement. During this
period the patient also developed a persistent right facial
nerve palsy. The patient was treated with one dose of
intrathecal methotrexate, followed by five courses of high
dose intravenous methotrexate with leucovorin rescue over
the ensuing weeks. Subsequently, the patient improved
clinically and was able to eventually transition from
inpatient to outpatient neurorehabilitation. On discharge
from the rehabilitation program, the patient was alert and
oriented to all spheres with improved higher cognitive
function and, with the exception of the right facial droop,
an intact motor and sensory exam. The postoperative MRI
at 1 month showed almost complete resolution of brainstem
and cerebral lesions (Fig. 1c, d). The patient continued to
do well until 11 months when MRI showed recurrence of
disease. The patient was then treated with temozolomide
but subsequently succumbed to the disease at 15 months.
Histologic examination Brainstem biopsy specimen
showed atypical lymphocytic infiltrate with prominent
reactive astrocytosis and spongiform changes in the white
matter (Fig. 2a, b). Subpial spread of malignant cells was
Table 1 Summary of the clinical characteristics from previous reports of primary CNS T-cell lymphoblastic lymphoma (M male, F female, AMS
altered mental status, MTX methotrexate, NR not reported, RT radiotherapy, H/A headache, Bx biopsy, TMX temozolomide)
Reference Age(years)/ sex Presentation Imaging Location Treatment Survival
(months)
[21] 52/M AMS Normal Leptomeninges Intrathecal MTX 1.5
[4] 2/F NR CT; iso/ hyper Cerebellum Surgery, RT, chemo 24, without
recurrence
[11] 63/F H/A, dysphasia,
hemiparesis
CT; enhancing Multicentric;
subfalcine, L frontal
Bx, RT, chemo 11
[20] NR/NR NR NR NR NR NR
[19] 54/M Aphasia CT; hypo Frontal, L caudate RT 1
Present case 56/M AMS CT; hypo,
T2/FLAIR; hyper
Brainstem, L frontal,
cerebellum
Intrathecal MTX,
IV MTX, TMZ
15, with
recurrence at 11
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noted in the cortical specimen (Fig. 2c). Immunohisto-
chemical analysis demonstrated positive staining for the T-
cell marker CD3 (Fig. 2d), CD7, CD45, CD10, CD99 (data
not shown), and were weakly positive for both CD1a and
CD5 (data not shown). Staining for CD4 was equivocal.
CD8, CD34, and CD 68 were negative, as was staining for
the B-cell marker CD20 (data not shown). Malignant cells
were also positive for TdT (Fig. 2e). The specimen also
exhibited a high Ki-67 labeling index (Fig. 2f). CSF
analysis showed atypical lymphoid cells consistent with
precursor T-cell lymphoblastic lymphoma/leukemia. Bone
marrow biopsy demonstrated no evidence of malignancy.
Discussion and review of the literature
Lymphoblastic lymphomas are characterized by medium-
sized blast cells with a high nuclear to cytoplasmic ratio,
fine chromatin, and inconspicuous nucleoli [5]. As in the
present case, immunophenotyping demonstrating CD3 and
TdT positivity confirms the diagnosis of T-cell lympho-
blastic lymphoma. TPCNSL of the lymphoblastic type is an
extremely rare tumor with only five reported cases in the
literature (Table 1) [4, 11, 19–21]. Of the four which
provided clinical characteristics, two were supratentorial,
one was leptomeningeal, and one was located in the
cerebellum. In contrast, the present tumor was located in
the pons with diffuse extension to brainstem, cerebellar, and
cerebral structures. Taken together, these findings parallel
those of the single large multicenter study of TPCNSL,
which reported that the majority of these tumors are located
supratentorially [22].
Additional clinical characteristics of the lymphoblastic type
are similar to those of TPCNSL. The overall median age of
patients with TPCNSL is 60 [22]. With the exception of one
case report describing a 2-year-old female [4], the remaining
cases and ours involve patients in the fifth and sixth decades
[11, 19, 21]. There is a male predominance of TPCNSL [22].
Fig. 1 Axial MRI obtained be-
fore biopsy shows diffuse
hyperintensity on T2-weighted
images in the pons (a) and
extending to the temporal lobes
bilaterally (b). Preoperative
FLAIR image also demonstrates
the lesion in the pons and
temporal lobes (c). One month
postoperative and post-
chemotherapy axial T2-
weighted images demonstrate
substantial resolution of the le-
sion in the pons (d) and cerebral
hemispheres (e)
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Including the present report, 3/5 (60%) of the reported cases
of lymphoblastic type TPCNSL are male [19, 21]. In the
present report, lumbar puncture revealed an elevated CSF
protein, which was true in 79% of TPCNSL [22].
One previously reported patient with leptomeningeal
disease presented with altered mental status, as did the
present patient [21]. The two remaining reports which
described presenting symptoms demonstrated focal neuro-
logic deficits: dysphasias and hemiparesis, which were
consistent with their locations in the left frontal lobe [11,
19]. These observations underscore the diversity of pre-
sentations possible in this rare disease. Primary CNS
lymphoma can be difficult to distinguish from other
neurologic diseases [14]. Interestingly, there is one case
report of Lyme neuroborreliosis initially misdiagnosed as
CNS lymphoma, which led to delay in treatment [24].
Conversely, in the present case, the patient presented with a
history of positive Lyme serology and MRI findings
consistent with cranial neuritis. When the patient failed to
respond to antibiotic and corticosteroid treatment, brain
biopsy was performed. Since this tumor is responsive to
methotrexate and other chemotherapy treatment, it is
important to maintain a high index of suspicion when
evaluating patients with non-focal neurologic manifesta-
tions and diffuse imaging abnormalities. Early brain biopsy
should be considered to obtain a definitive diagnosis.
Imaging features of lymphoblastic TPCNSL appear to be
variable. Previous reports utilized CT scanning (Table 1).
One tumor demonstrated enhancement after contrast ad-
ministration [11]. One tumor was hyperdense relative to
gray matter and one was hypodense [4, 19]. CT imaging in
the present report demonstrated subtle diffuse hypodensity
Fig. 2 Pathologic specimens
obtained from stereotactic biop-
sy demonstrated diffuse lym-
phocytic infiltrate in the
specimen from the pons (a).
Spongiform changes in the
white matter and malignant in-
filtration in Virchow-Robbins
spaces were also noted. Magni-
fication of 100× demonstrates
malignant lymphocytes (b). The
cortical specimen demonstrated
subpial infiltration (c). The ma-
lignant lymphocytes present in
the specimen from the pons
stained positive for CD3 (d) and
TdT (e). The specimen demon-
strated a high Ki-67 labeling
index(f)
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in the brainstem. This variability in CT imaging is in
contrast to other primary CNS lymphomas which are
generally hyperdense and universally enhancing [10]. A
recent series of MRI analysis of seven patients with
TPCNSL reported that the majority of these tumors present
radiographically as mass lesions that are hypointense on
T1-weighted images and hyperintense on T2-weighted
images which enhance [16]. While imaging in the present
study demonstrated high T2 signal intensity, the abnormal-
ity was diffusely infiltrative with no enhancement after
contrast administration.
Median survival for TPCNSL is 25 months [22]. A prior
case series and literature review suggested that pathology
might be predictive of survival, with a higher frequency of
long-term survivors having low-grade lymphocytic
TPCNSL [23]. A larger, more recent retrospective study
showed no difference in survival based on low-grade versus
anaplastic histologic features [22]. Of the four previous
reports of lymphoblastic TPCNSL, only one patient
survived for greater than 1 year [4]. The patient in the
present case relapsed after 11 months and succumbed to the
disease at 15 months despite salvage therapy. Taken
together, these data suggest a shorter survival for patients
with TPCNSL of the lymphoblastic type. Recent multicen-
ter studies of primary CNS lymphoma, including patients
with TPCNSL treated with high-dose methotrexate in
combination with procarbazine and vincristine, have dem-
onstrated prolonged survival relative to single agent therapy
[1, 3, 7, 13]. Others have demonstrated improved survival
in patients treated with methotrexate and osmotic blood-
brain barrier disruption [6]. Preliminary analysis of three
patients with TPCNSL treated with blood brain barrier
disruption and intra-arterial methotrexate showed similar
encouraging responses [8]. Future studies examining the
affect of newer treatment regimens such as these would be
difficult for TPCNSL of the lymphoblastic type due to the
rarity of the disease. However, this type of study would be
necessary before definitively designating this histology as a
poor prognostic indicator.
Conclusions
TPCNSL of the lymphoblastic type is an extremely rare
disease, with only five previously reported cases in the
literature. The cases reported demonstrate that this is a
diverse disease with variable clinical presentations, anatomic
locations, and imaging findings. Because of the possibility of
misdiagnosis and rapid progression, early biopsy appears to
be indicated to obtain a definitive diagnosis and facilitate
institution of appropriate chemotherapy. Nevertheless, it
appears that lymphoblastic TPCNSL confers a worse
prognosis than other types of TPCNSL.
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